Drugs / BR3006A
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06890299 Comparator | Dec 2024 → Jan 2025 | type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06890286 Comparator | Dec 2024 → Jan 2025 | type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR3006A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06890299 ↗ |